

**From:** [WHITE Donna](#)  
**To:** [AGO - High Cost Prescription Drugs](#)  
**Cc:** [PIDDINGTON Amie](#)  
**Subject:** New Drug Submission  
**Date:** Tuesday, July 21, 2020 9:48:07 AM  
**Attachments:** [image167443.png](#)

---

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

Dear Vermont Department of the Attorney General,

Chiesi USA, Inc. would like to report a new product, Ferriprox® (deferiprone) 1000mg Twice-a-Day Tablets.


1. Marketing and Pricing Plan – Small commercial team (5 – 7 people) discussing patient benefits with healthcare professionals who treat Thalassemia; direct promotion only.
2. Estimated Volume of Patients – At peak, we anticipate 650 patients nationwide. Vermont could have as few as zero.
3. The drug was not granted breakthrough therapy designation or priority review by the FDA, although it is used for a rare disease
4. The drug was developed by the manufacturer.

Chiesi USA, Inc. has not divulged additional information into the public domain.

Best Regards,

**Donna White, CCEP**  
*Vice President, Compliance*

**Chiesi USA Inc.**  
175 Regency Woods Place, Ste. 600, Cary, NC 27518 (USA)  
Office +1 (919) 678-6611 x1528 - Fax +1 (866) 441-5282  
Mobile +1 (919) 946-1437  
[www.chiesiusa.com](http://www.chiesiusa.com)



The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. If the reader of this message is not the intended recipient, you are hereby notified that your access is unauthorized, and any review, dissemination, distribution or copying of this message including any attachments is strictly

prohibited. If you are not the intended recipient, please contact the sender and delete the material from any computer.